RedHill Bizerma赢得了对Kukbo的约1050万美元判决; RedHill已获得韩国法院针对Kukbo的扣押赠款，旨在防止Kukbo在判决执行之前处置资产

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd ("Kukbo") is now final and eligible for enforcement and foreign recognition, with no further appeal permissible following expiry of the appeal period.

The Court has awarded more than $10.5 million in total to RedHill, comprised of the main judgment of approximately $8.6 million, now final and eligible for enforcement, and the award for legal fees and expenses of approximately $1.9 million (both include the principal amounts and accrued interest, to date) which remains subject to appeal until March 13, 2026. 9% annual statutory interest continues to accrue on both awards.

In addition, RedHill has secured a Korean court attachment grant against Kukbo aimed at preventing Kukbo from disposing of assets prior to judgment enforcement.